The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection
People with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular disease (CVD) and kidney disease. This enhanced cardio-renal risk persists despite improvements in care and treatments over the last 20 years. Intensive glucose control alone does not substantially reduce the r...
Saved in:
Main Author: | J. Karalliedde |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2021-04-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4323 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ISCHEMIC HEART DISEASE AND RENAL DYSFUNCTION
by: F. I. Belyalov
Published: (2017-07-01) -
Posterior Reversible Encephalopathy Syndrome in Chronic Kidney Disease: Incidence, Outcomes, and Risk Factors in a National Cohort
by: Mingyue He, et al.
Published: (2025-07-01) -
Effect of Pulmonary Hypertension Severity on Graft Function and Quality of Life after Transplantation in Patients with End-Stage Renal Disease
by: susan Mohammadi-Kebar, et al.
Published: (2022-01-01) -
Emergency Department Presentations of Chronic Kidney Disease in a Tertiary Hospital of Nepal: A Cross-sectional study
by: Ram Prasad Neupane, et al.
Published: (2025-06-01) -
Five-Year Survival Rate of Patients with End-Stage Renal Disease on Continuous Ambulatory Peritoneal Dialysis (CAPD) at Malang CAPD Center, Indonesia
by: Atma Gunawan, et al.
Published: (2023-03-01)